Avinger (NASDAQ:AVGR) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Avinger (NASDAQ:AVGRFree Report) in a report issued on Friday. The firm issued a sell rating on the medical device company’s stock.

Separately, HC Wainwright reiterated a buy rating and set a $24.00 target price on shares of Avinger in a research report on Friday, July 28th.

Read Our Latest Research Report on AVGR

Avinger Price Performance

Avinger stock opened at $6.07 on Friday. Avinger has a 1-year low of $4.14 and a 1-year high of $24.30. The stock has a market cap of $4.37 million, a PE ratio of -0.15 and a beta of 1.62. The stock’s fifty day moving average is $10.43 and its two-hundred day moving average is $10.27.

Avinger (NASDAQ:AVGRGet Free Report) last posted its quarterly earnings results on Thursday, July 27th. The medical device company reported ($8.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($7.35) by ($1.50). Avinger had a negative net margin of 208.86% and a negative return on equity of 6,767.92%. The business had revenue of $2.04 million during the quarter, compared to analyst estimates of $2.30 million. On average, research analysts expect that Avinger will post -19.79 earnings per share for the current fiscal year.

Institutional Trading of Avinger

Hedge funds and other institutional investors have recently made changes to their positions in the company. Armistice Capital LLC increased its position in shares of Avinger by 7.8% during the fourth quarter. Armistice Capital LLC now owns 720,136 shares of the medical device company’s stock worth $781,000 after purchasing an additional 52,000 shares in the last quarter. Dimensional Fund Advisors LP acquired a new stake in shares of Avinger during the first quarter worth about $64,000. Renaissance Technologies LLC acquired a new stake in shares of Avinger during the second quarter worth about $42,000. Finally, Prosperity Wealth Management Inc. acquired a new position in Avinger in the 2nd quarter valued at about $49,000. Institutional investors and hedge funds own 8.14% of the company’s stock.

About Avinger

(Get Free Report)

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.

Recommended Stories

Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.